What is indigestion and how we can we treat it? Review article
Article Sidebar
Main Article Content
Abstract
One of the most common reasons for visiting a doctor’s office, not only specialist ones, is the feeling of indigestion, postprandial fullness, flatulence and discomfort in the epigastrium reported by patients. These symptoms are very non-specific, they may concern dyspepsia, functional disorders of the gallbladder and bile ducts, but also functional disorders of the irritable bowel type. Diagnosis is difficult due to frequent overlap syndromes, and treatment includes pharmacological treatment, including antispasmodic and analgesic drugs, as well as surgical procedures, e.g. sphincterotomy of the sphincter of Oddi or cholecystectomy. It is important to remember to individualize the procedure, especially when qualifying for surgical treatment.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Talley NJ, Phung N, Kalantar JS. Indigestion: When is it functional? BMJ. 2001; 323: 1294. https://doi.org/10.1136/bmj.323.7324.1294.
3. Gabbard S, Vijayvargiya N. Functional dyspepsia: How to manage the burn and the bloat. Cleve Clin J Med. 2024; 91 (5): 301-7. https://doi.org/10.3949/ccjm.91a.23062.
4. Sobol E, Muszyński J. Dyskinezy dróg żółciowych. Przewodnik Lekarza. 2005; 3: 98-106.
5. Nowakowska-Duława E, Nowak A. Postępy w diagnostyce i leczeniu chorób dróg żółciowych. Postępy Nauk Medycznych. 2001; 2: 3-13.
6. Daniel P, Małecka-Wojciesko E, Gąsiorowska A et al. Choroby pęcherzyka i dróg żółciowych. In: Interna Szczeklika. Medycyna Praktyczna, Warszawa 2022: 1176-8.
7. Waśko-Czopnik D. Digestive disorders due to dyskinesis of bile tract – can we treat them? Lekarz POZ. 2024; 10(1): 71-5.
8. Panek-Jeziorna M, Mulak A. Rola kwasów żółciowych w patogenezie chorób jelit. Postepy Hig Med Dosw. 2017; 71: 737-46.
9. Ridlon JM, Alves JM, Hylemon PB et al. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013; 4: 382-7.
10. Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci USA. 2006; 103: 4333-4.
11. Zhao Y, Wu J, Li JV et al. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013; 12: 2987-99.
12. Pavlidis P, Powell N, Vincent RP et al. Systematic review: bile acids and intestinal inflammation – luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther. 2015; 42: 802-17.
13. Duboc H, Rainteau D, Rajca S et al. Increase in fecal primary bile acids and dysbiosisin patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012; 24: 513-20.
14. Mulak A, Smereka A, Paradowski L. Nowości i modyfikacje w Kryteriach Rzymskich IV. Gastroenterol Klin. 2016; 8: 52-61.
15. Dior M, Delagrèverie H, Duboc H et al. Interplay between bile acid metabolism and microbiota in irritablebowel syndrome. Neurogastroenterol Motil. 2016; 28: 1330-40.
16. Cotton PB, Elta GH, Carter CR et al. Gallbladder and sphincter of Oddi disorders. Gastroenterology. 2016; 150: 1420-9.
17. Starlitz M. Pharmacology of the sphincter of Oddi. Endoscopy. 1988; 20(Suppl. 1): 171-4.
18. Dufek V. Stenosis f the papilla of Vater – clinical picture and possibilities of therapy. Vnitr Lek. 1994; 40: 382-5.
19. Drease K, Hirche H. Pharmacological effects on the motor activity of Oddi’s sphincter. Postoperative electromanometric measurement of the bile ducts. Frtschr Med. 1980; 98: 1529-33.